Experimental drug more effective in treating rare kidney disease

New study finds that experimental drug sparsentan is an effective treatment for the rare kidney disease focal segmental glomerulosclerosis, which currently has no FDA-approved therapies.

from Latest Science News -- ScienceDaily https://ift.tt/2OSHxYJ